anchor instance (Q104473)

From ScienceSource
Jump to: navigation, search
No description defined
edit
Language Label Description Also known as
English
anchor instance
No description defined

    Statements

    UPCR had decreased to 0.23 at the 1-year follow-up. Therefore, tocilizumab is beneficial in treating
    0 references
    secondary to SJIA when conventional therapies fail. However, the minimum dose of tocilizumab in such
    0 references
    808
    0 references
    193
    0 references
    17,296
    0 references
    17 April 2019
    0 references
    0 references
    Clinical improvement of renal amyloidosis in a patient with systemic-onset juvenile idiopathic arthritis who received tocilizumab treatment: a case report and literature review. (5429510)
    0 references
     
    edit
      edit
        edit
          edit
            edit
              edit